Evaluating the Efficacy of the Combination of Multi-zonal Contact Lens and Atropine for Controlling Myopia Progression

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06765603

Enrollment

180

Registered

2025-01-09

Start date

2025-02-01

Completion date

2029-12-31

Last updated

2025-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Keywords

myopia intervention

Brief summary

The aim of the study is to explore efficacy of combination Atropine and multifocal CL. Randomized Control Trial including 4 arms: Atropine / multizonal CL; Atropine/ SV CL, Placebo drop/ multizonal CL; Placebo drop/ SV CL. Followed over 1 year with outcome measure of change in spherical equivalent and axial length.

Detailed description

see above

Interventions

DRUGAtropine 0.025%

Atropine 0.025%

DEVICEMultizonal contact lens

Multizonal CL

DRUGPlacebo

Placebo

DEVICESingle vision Contact lens

Single vision contact lens

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

RCT

Eligibility

Sex/Gender

ALL

Age

7 Years to 13 Years

Healthy volunteers

Inclusion criteria

* Between 7 and 12 (inclusive) years of age at the time of screening. * spherical equivalent of cycloplegic objective refraction (by autorefraction) range of -0.75 D to -4.50 D (inclusive) in each eye. * Refractive cylinder less than 1.12 D (inclusive) * Best-corrected visual acuity (BCVA) of 0.04 logMAR or better in each eye, with difference less than 0.20 logMAR between eyes. * Have normal eyes (i.e., no ocular medications or infections of any type).

Exclusion criteria

* Past or current use of myopia control treatment or involvement in previous myopia control study * Any current or seasonal use of ocular medication (eg. for allergy or chronic blepharitis). * hypersensitivity or allergic reaction to atropine, cyclopentolate, topical anesthetics or study approved rewetting drop solutions available in local markets. * previous history or signs of a contact lens-related corneal inflammatory event (e.g., past ulcer or scar) that may contraindicate contact lens wear. * Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, ocular hypertension, glaucoma, history of recurrent corneal erosions, aphakia, uveitis, severe keratoconjunctivitis sicca, keratoconus, keratoconus suspect, and pellucid marginal degeneration. * Grade 3 or greater palpebral conjunctival observations or any other Grade 2 or greater slit-lamp findings (eg. edema, corneal neovascularization, corneal staining, conjunctival injection) on the ISO 11980 classification scale. * Any central corneal scar or corneal distortion resulting from ocular diseases or previous hard or rigid permeable contact lens wear.

Design outcomes

Primary

Measure	Time frame	Description
Change in spherical equivalent	12 months	Change in spherical equivalent at 12 months

Secondary

Measure	Time frame	Description
Change in axial length	12 months	Change in axial length at 12 months

Contacts

Primary Contactaudrey chia, PhD

audrey.chia.w.l@singhealth.com.sg65 62277255

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026